Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

IDO1 expression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

IDO1 expression	Non Small Cell Lung Cancer	IDO1 expression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials AACR 2023 - 1 week (New C3) Immunotherapy Sensitive : C3 AACR 2023 - 1wk	Immunotherapy Sensitive: C3 – Early Trials AACR 2023 - 1 week Immunotherapy Sensitive : C3 AACR 2023 - 1 week - (New C3)
IDO1 expression	Melanoma	IDO1 expression	Melanoma	nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria nivolumab + ipilimumab Sensitive : C2	nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria nivolumab + ipilimumab Sensitive : C2
IDO1 expression	Melanoma	IDO1 expression	Melanoma	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2
IDO1 expression	Melanoma	IDO1 expression	Melanoma	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2